- Home
- TNXP vs FOA Comparison
TNXP vs FOA Comparison
Compare TNXP & FOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- FOA
- Stock Information
- Founded
- TNXP 2007
- FOA 2013
- Country
- TNXP United States
- FOA United States
- Employees
- TNXP N/A
- FOA N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- FOA Finance Companies
- Sector
- TNXP Health Care
- FOA Finance
- Exchange
- TNXP Nasdaq
- FOA Nasdaq
- Market Cap
- TNXP 335.6M
- FOA 292.6M
- IPO Year
- TNXP N/A
- FOA N/A
- Fundamental
- Price
- TNXP $26.54
- FOA $27.80
- Analyst Decision
- TNXP Buy
- FOA Buy
- Analyst Count
- TNXP 1
- FOA 2
- Target Price
- TNXP $70.00
- FOA $27.50
- AVG Volume (30 Days)
- TNXP 1.9M
- FOA 109.5K
- Earning Date
- TNXP 08-11-2025
- FOA 11-05-2025
- Dividend Yield
- TNXP N/A
- FOA N/A
- EPS Growth
- TNXP N/A
- FOA N/A
- EPS
- TNXP N/A
- FOA 7.10
- Revenue
- TNXP $9,831,000.00
- FOA $527,520,999.00
- Revenue This Year
- TNXP $21.19
- FOA $21.89
- Revenue Next Year
- TNXP $722.94
- FOA $10.33
- P/E Ratio
- TNXP N/A
- FOA $3.88
- Revenue Growth
- TNXP N/A
- FOA 46.94
- 52 Week Low
- TNXP $6.76
- FOA $8.69
- 52 Week High
- TNXP $130.00
- FOA $32.40
- Technical
- Relative Strength Index (RSI)
- TNXP 32.47
- FOA 58.57
- Support Level
- TNXP $34.50
- FOA $25.45
- Resistance Level
- TNXP $29.70
- FOA $26.80
- Average True Range (ATR)
- TNXP 3.35
- FOA 1.24
- MACD
- TNXP -1.55
- FOA -0.10
- Stochastic Oscillator
- TNXP 4.29
- FOA 66.20
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.